{ "schema_version": "deep-research.report.v1", "id": "consumer-downgrade-health-silver-economy-78a2530a", "slug": "consumer-downgrade-health-silver-economy-78a2530a", "topic_id": "consumer-downgrade-health-silver-economy", "generated_at": "2026-05-19T14:04:25.020350+00:00", "metadata_generated_at": "2026-05-20T01:48:45.240124+00:00", "date": "2026-05-19", "source_fetch": "2026-05-19T12:49:36.748Z", "daily_date": "2026-05-19", "title": { "zh": "消费降级、银发经济与大健康结构性机会", "en": "Consumer Downgrade, Silver Economy, and Structural Healthcare Opportunities" }, "thesis": { "zh": "消费链条正在从总量弹性转向结构分化：银发消费、医疗健康、糖替代和 B 端餐饮渗透可能形成防御性需求，但需要验证支付能力和渠道真实动销。", "en": "Consumption is shifting from aggregate beta to structural divergence: silver-economy demand, healthcare, sugar substitutes, and B-end catering penetration may create defensive demand, but purchasing power and channel sell-through must be validated." }, "questions": { "zh": [ "消费降级下哪些子行业仍具备真实需求韧性？", "银发消费和大健康是长期底座还是短期防御交易？", "糖替代、餐饮 B 端和医疗链条如何验证动销质量？" ], "en": [ "Which subsectors retain real demand resilience under consumer downgrade?", "Are silver-economy and healthcare themes a durable base or a defensive trade?", "How should sugar substitutes, B-end catering, and healthcare chains validate sell-through quality?" ] }, "keywords": [ "消费", "消费降级", "银发", "养老金", "大健康", "医疗", "医药", "糖", "GLP-1", "餐饮", "B端", "动销", "healthcare" ], "chains": [ { "label_zh": "生产率与效率", "label_en": "productivity and efficiency" }, { "label_zh": "宏观通胀传导", "label_en": "macro inflation transmission" } ], "counts": { "evidence": 12, "risks": 6, "analysts": 2, "source_sentences": 364 }, "analysts": [ { "name_zh": "未标注分析师", "name_en": "unlabeled analyst", "evidence_count": 11 }, { "name_zh": "首席策略师", "name_en": "首席策略师", "evidence_count": 1 } ], "evidence": [ { "rank": 1, "title_zh": "验证食品加工链下游需求端：B端餐饮渗透与GLP-1对糖替代品的消费驱动", "title_en": "Downstream food-processing demand: B-end catering penetration and GLP-1 sugar-substitute pull", "analyst_zh": "未标注分析师", "analyst_en": "unlabeled analyst", "date": "2026-05-18", "href": "reports/archive-176d7dbc3d4b", "source": "archive-176d7dbc3d4b", "source_path": "frontend/generated/reports/archive-176d7dbc3d4b.json", "source_sentence_count": 17, "tags": [ "宏观", "风险" ], "score": 23.3, "summary_zh": "验证食品加工链下游需求端：B端餐饮渗透与GLP-1对糖替代品的消费驱动。 截至2026年5月18日，食品加工行业的复苏并非虚假繁荣，而是由两条极具确定性的需求主线驱动：一是餐饮行业在极致降本诉求下对B端半成品的加速渗透；二是GLP-1药物普及带来的全球“减糖”革命对阿洛酮糖等新型代糖的爆炸性需求。 GLP-1类药物（如司美格鲁肽）在全球的广泛处方，不仅是医药事件，更是消费领域重大的破坏性创新。", "summary_en": "The source validates two defensive growth lines in food processing: restaurant operators using B-end semi-finished products to lower labor and kitchen costs, and GLP-1-driven sugar reduction supporting allulose and other next-generation sweeteners.", "implication_zh": "提示消费降级并不等于所有消费链条走弱，降本和健康替代可能同时创造结构性需求。", "implication_en": "Shows that consumer downgrade can coexist with structural demand created by cost reduction and healthier substitution." }, { "rank": 2, "title_zh": "研究记录04｜养老金体系转型与银发消费底座（压力测试）", "title_en": "Pension-system transition and the silver-economy consumption base", "analyst_zh": "未标注分析师", "analyst_en": "unlabeled analyst", "date": "2026-05-18", "href": "reports/archive-d1a519e59bbc", "source": "archive-d1a519e59bbc", "source_path": "frontend/generated/reports/archive-d1a519e59bbc.json", "source_sentence_count": 35, "tags": [ "通胀", "宏观", "风险" ], "score": 15.9, "summary_zh": "压力测试/部分否定 研究记录03 关于\"银发经济 16 万亿\"线性外推到自费医疗的隐含假设——养老金+地产双约束下，自费弹性应下修。 养老金体系转型在十五五（2026-2030）期间能为大健康内需提供 结构性但不充裕 的支撑：第一支柱替代率下行 + 第二支柱覆盖窄 + 第三支柱个人养老金渗透率低，叠加地产财富效应明显衰减，使得 60+ 人群可自由支配的\"健康消费现金流\"远低于市场基于\"银发经济 16 万亿\"的线性外推。 研究记录04｜…", "summary_en": "The pension stress test argues that silver-economy healthcare demand is real but cash-flow constrained: basic medical insurance and long-term care insurance support rigid demand, while high-end self-pay medical services need lower expectations.", "implication_zh": "把银发经济从总规模叙事拆成可支付现金流、政策支付和自费弹性三部分，防止高端自费医疗被过度外推。", "implication_en": "Separates the silver-economy headline from actual cash-flow support, policy reimbursement, and self-pay elasticity." }, { "rank": 3, "title_zh": "消费降级风险对“以旧换新”驱动力的影响评估", "title_en": "Consumer-downgrade risk and the quality of trade-in replacement demand", "analyst_zh": "未标注分析师", "analyst_en": "unlabeled analyst", "date": "2026-05-18", "href": "reports/archive-ec81fa143f74", "source": "archive-ec81fa143f74", "source_path": "frontend/generated/reports/archive-ec81fa143f74.json", "source_sentence_count": 24, "tags": [ "宏观", "风险" ], "score": 9.8, "summary_zh": "research note 指出新华财经-家装产业链指数 30 日激活率仅 4%（8/198），核心源于市场对“消费降级 → 家装总盘子萎缩”的悲观假设。 支持 research note 的方向性判断，但需对“红利兑现节奏”做结构性下修： 消费降级并不会整体抹平“以旧换新”政策红利，却会显著重塑红利分布——客单价被压缩、品类向“刚需替换 + 适老化 + 局部翻新”集中、品牌端的强者愈强（白牌出清加速）。 衔接：承接 research…", "summary_en": "The trade-in demand note warns that policy stimulus and replacement demand must be separated from true discretionary recovery; sell-through, subsidy intensity, and household balance-sheet pressure determine earnings quality.", "implication_zh": "要求用客单价、折扣率、信用压力和真实动销验证政策刺激或高端消费韧性。", "implication_en": "Requires validation through ticket size, discount rate, credit stress, and real sell-through rather than headline demand." }, { "rank": 4, "title_zh": "全球宏观压力测试报告：医疗行业与生物安全法案的成本锚点 (v2.0)", "title_en": "Healthcare cost anchor under the Biosecure Act and CXO decoupling", "analyst_zh": "未标注分析师", "analyst_en": "unlabeled analyst", "date": "2026-05-16", "href": "reports/archive-85e0f6a59595", "source": "archive-85e0f6a59595", "source_path": "frontend/generated/reports/archive-85e0f6a59595.json", "source_sentence_count": 22, "tags": [ "通胀", "宏观", "A股", "港美股", "风险" ], "score": 8.5, "summary_zh": "我们认为，医疗行业——特别是以 $BIOSECURE\\ Act$ 为核心的 CXO 脱钩进程——在政治成本树中扮演着“通胀/研发成本缓冲器”的角色。 尾部风险 (14%)；受限于美国选民对医疗价格的敏感度。 压力测试显示：在 场景 B2 (受控竞争) 下，当前的 2032 年宽限期是维持美方医药创新领先地位的“合规底线”。", "summary_en": "The healthcare macro stress test treats Biosecure Act risk, CXO decoupling, and compliance cost as a cost anchor that can change the margin profile of healthcare globalization.", "implication_zh": "把大健康机会放入政策、合规、出海订单和回款节奏的利润率压力测试中。", "implication_en": "Places healthcare upside inside a margin stress test for policy, compliance, outbound orders, and cash collection." }, { "rank": 5, "title_zh": "创新药与医疗器械研发：截至2026-05-14的政策驱动重估", "title_en": "Policy-driven repricing of innovative drugs and medical-device R&D", "analyst_zh": "未标注分析师", "analyst_en": "unlabeled analyst", "date": "2026-05-14", "href": "reports/archive-84601f337750", "source": "archive-84601f337750", "source_path": "frontend/generated/reports/archive-84601f337750.json", "source_sentence_count": 66, "tags": [ "通胀", "A股", "港美股", "风险" ], "score": 6.9, "summary_zh": "这说明代谢创新已不再只是糖尿病专科市场，而是依从性和慢性体重管理平台。 截至2026-05-14，我支持前序研究关于地缘科技风险溢价正在重定价的主线，但医药板块的重估机制不同：它不是由单一外交事件触发，而是由临床风险出清、支付改革和跨境授权验证共同推动。 医药行业对应芯片出口管制的变量，是生物安全和供应链筛查。", "summary_en": "The policy repricing note supports innovative drugs and medical devices, but the upside depends on reimbursement, procurement, product approval, and commercialization cadence rather than broad sector beta.", "implication_zh": "把大健康机会放入政策、合规、出海订单和回款节奏的利润率压力测试中。", "implication_en": "Places healthcare upside inside a margin stress test for policy, compliance, outbound orders, and cash collection." }, { "rank": 6, "title_zh": "2026年大健康结构性机会的组合权重与A/H股交易路径", "title_en": "Healthcare structural opportunities and A/H-share portfolio path", "analyst_zh": "首席策略师", "analyst_en": "首席策略师", "date": "2026-05-19", "href": "reports/archive-cf3e4c1b2af9", "source": "archive-cf3e4c1b2af9", "source_path": "frontend/generated/reports/archive-cf3e4c1b2af9.json", "source_sentence_count": 16, "tags": [ "宏观", "A股", "港美股", "风险", "权益策略" ], "score": 5.3, "summary_zh": "在2026-05-19的时间节点上，针对前期调研（医药行业分析师与生物科技分析师）反馈的结论，大健康产业的超额收益已从“全面创新”转向结构性赛道。 GLP-1 产业链全球需求高涨带来极高的业绩弹性，但考虑到 FDA 监管、海外交付节奏以及潜在地缘风险，必须对其给予明显的“履约折扣”。 作为港股（H股）18A板块的优质Alpha标的，随着外资对中国核心生物医药资产的重估，采取 Buy & Hold 策略，淡化短期波动。", "summary_en": "The strategy report proposes a barbell healthcare portfolio: high-certainty Hong Kong-listed anchors and tactical A-share high-beta positions, with different holding periods and risk discounts.", "implication_zh": "把大健康机会放入政策、合规、出海订单和回款节奏的利润率压力测试中。", "implication_en": "Places healthcare upside inside a margin stress test for policy, compliance, outbound orders, and cash collection." }, { "rank": 7, "title_zh": "美国金融板块分析：消费信贷应力的传导与定价", "title_en": "Consumer-credit stress transmission and financial-sector pricing", "analyst_zh": "未标注分析师", "analyst_en": "unlabeled analyst", "date": "2026-05-18", "href": "reports/archive-856a93528acf", "source": "archive-856a93528acf", "source_path": "frontend/generated/reports/archive-856a93528acf.json", "source_sentence_count": 24, "tags": [ "通胀", "A股", "能源", "风险" ], "score": 5.3, "summary_zh": "移交至： chief-risk [reviewer, trigger a/c]。 “滞胀式挤压”正在积极侵蚀美国底层 40% 消费者的偿付能力。 信用迁移： 除消费信贷外，K 型经济正在伤害小微企业（SMB）。", "summary_en": "The credit-stress report is a household purchasing-power cross-check: weaker consumer credit quality can cap discretionary healthcare, premium experience consumption, and replacement demand.", "implication_zh": "要求用客单价、折扣率、信用压力和真实动销验证政策刺激或高端消费韧性。", "implication_en": "Requires validation through ticket size, discount rate, credit stress, and real sell-through rather than headline demand." }, { "rank": 8, "title_zh": "研究记录08｜内需刚性化与离岸美元期权约束下的A股大健康配置策略 — 2026-05-18", "title_en": "A-share healthcare allocation under rigid domestic demand and offshore-dollar constraints", "analyst_zh": "未标注分析师", "analyst_en": "unlabeled analyst", "date": "2026-05-18", "href": "reports/archive-f90a6789442a", "source": "archive-f90a6789442a", "source_path": "frontend/generated/reports/archive-f90a6789442a.json", "source_sentence_count": 48, "tags": [ "通胀", "宏观", "A股", "风险" ], "score": 5.3, "summary_zh": "2026-2027 年政策允许个人养老金余额提前用于重大医疗支出，恢复自费医疗弹性。 低配 纯自费消费医疗 和 只有license-out headline的故事股；。 截至 2026-05-18，我对前序研究的综合判断是：A股大健康策略 不是 放弃跨境BD，而是停止把跨境BD当成组合核心。", "summary_en": "The allocation note frames domestic healthcare as a rigid-demand A-share exposure, but warns that offshore-dollar constraints and global risk appetite affect valuation and capital-flow timing.", "implication_zh": "为消费降级下的结构性机会提供交叉验证，重点是支付能力、动销质量和现金流兑现。", "implication_en": "Provides cross-checking evidence for structural opportunities under consumer downgrade, with focus on purchasing power, sell-through quality, and cash-flow conversion." }, { "rank": 9, "title_zh": "战略分析：阿洛酮糖成本曲线压缩背景下的百龙创园（605016）配置价值", "title_en": "Bailong Chuangyuan and the allulose cost-curve compression thesis", "analyst_zh": "未标注分析师", "analyst_en": "unlabeled analyst", "date": "2026-05-18", "href": "reports/archive-686a97ab432f", "source": "archive-686a97ab432f", "source_path": "frontend/generated/reports/archive-686a97ab432f.json", "source_sentence_count": 20, "tags": [ "通胀", "风险" ], "score": 5.3, "summary_zh": "因为其增长并非简单的价格周期驱动，而是 GLP-1 时代生物基甜味剂对高果糖浆（HFCS）的结构性替代。 将 605016 视为纯粹代糖主题的投资者会被价格波动洗出；而将其视为 “生物基精密制造平台” 的投资者将能捕捉到显著的相对价值。 虽然市场担忧成本曲线的下移（正如研究记录04所述，现金成本从 25-32元/kg 下压至 16-22元/kg），但本策略师认为，这种价格压缩是区分 “主题投机标的” 与 “结构性复利标的” 的终极过滤…", "summary_en": "The allulose thesis focuses on cost-curve compression, continuous production, by-product recycling, and Thai capacity as evidence that sweetener demand can become margin advantage for a cost leader.", "implication_zh": "提示消费降级并不等于所有消费链条走弱，降本和健康替代可能同时创造结构性需求。", "implication_en": "Shows that consumer downgrade can coexist with structural demand created by cost reduction and healthier substitution." }, { "rank": 10, "title_zh": "大健康产业链工业视角挑战 — 2026-05-18", "title_en": "Industrial challenge to healthcare-chain execution assumptions", "analyst_zh": "未标注分析师", "analyst_en": "unlabeled analyst", "date": "2026-05-18", "href": "reports/archive-74653855e8ab", "source": "archive-74653855e8ab", "source_path": "frontend/generated/reports/archive-74653855e8ab.json", "source_sentence_count": 48, "tags": [ "通胀", "宏观", "风险" ], "score": 5.3, "summary_zh": "前序研究认为大健康研究不足，这一点方向上成立；但它高估了2026年催化的即时性和确定性。 “十五五”规划在2026年3月获批，重点支持制造业、战略性新兴产业、生物医药、高端装备、机器人和航空航天，但我审阅的来源没有验证上述核心部件“90%国产化率”的统一目标。 更稳妥的结论应更窄：老龄化需求与设备更新创造多年收入池，但2026年的alpha取决于可验证的制造瓶颈、医院资本开支节奏、集采价格和核心部件替代。", "summary_en": "The industrial challenge asks whether healthcare demand can be fulfilled through capacity, delivery, manufacturing quality, and supply-chain execution rather than only through thematic demand.", "implication_zh": "为消费降级下的结构性机会提供交叉验证，重点是支付能力、动销质量和现金流兑现。", "implication_en": "Provides cross-checking evidence for structural opportunities under consumer downgrade, with focus on purchasing power, sell-through quality, and cash-flow conversion." }, { "rank": 11, "title_zh": "2026-05-18 外汇策略综合：生物医药出海BD浪潮下的离岸美元滞留", "title_en": "Outbound pharma BD and offshore-dollar retention", "analyst_zh": "未标注分析师", "analyst_en": "unlabeled analyst", "date": "2026-05-18", "href": "reports/archive-9fe252cff02d", "source": "archive-9fe252cff02d", "source_path": "frontend/generated/reports/archive-9fe252cff02d.json", "source_sentence_count": 22, "tags": [ "宏观", "A股", "港美股", "风险" ], "score": 5.3, "summary_zh": "截至2026年5月18日，综合宏观内需约束（研究记录03、04）与医疗行业的地缘政治摩擦（研究记录05、06），外汇市场的核心结论是：“全球BD/License-out”浪潮本质上是一个离岸美元滞留的故事，而非在岸人民币结汇的催化剂。 因此，大健康产业链的全球扩张成为了微观企业套息交易（Carry Trade）的驱动力：借入低息在岸人民币为研发融资，同时在离岸积累美元资产。 综合来看，A股和港股对这些创新药企的估值，本质上是对离岸美元…", "summary_en": "The outbound BD note links pharma globalization to offshore-dollar retention, deal timing, and cash repatriation, which can affect domestic valuation despite operating progress.", "implication_zh": "把大健康机会放入政策、合规、出海订单和回款节奏的利润率压力测试中。", "implication_en": "Places healthcare upside inside a margin stress test for policy, compliance, outbound orders, and cash collection." }, { "rank": 12, "title_zh": "消费行业分析：验证高端体验消费的ASP与利润率变动趋势", "title_en": "Premium experience consumption: ASP and margin validation", "analyst_zh": "未标注分析师", "analyst_en": "unlabeled analyst", "date": "2026-05-17", "href": "reports/archive-58ae5507bec4", "source": "archive-58ae5507bec4", "source_path": "frontend/generated/reports/archive-58ae5507bec4.json", "source_sentence_count": 22, "tags": [ "通胀", "宏观", "港美股", "风险" ], "score": 5.3, "summary_zh": "前序节点：中国宏观分析师 (china-macro) 提示五一人均消费下滑约0.7%，要求对高端体验消费的盈利逻辑进行压力测试。 我们建议剔除缺乏结构升级能力、单纯受损于ASP下滑的“伪体验消费”标的，坚定持有具备利润率护城河的龙头及稀缺演艺资产。 宏观数据反映的“流量稳健、人均消费微降”在微观层面得到印证。", "summary_en": "The premium-experience note stress-tests whether strong cruise and travel spending represent durable pricing power or a narrow high-income cohort that cannot offset broad consumer downgrade.", "implication_zh": "要求用客单价、折扣率、信用压力和真实动销验证政策刺激或高端消费韧性。", "implication_en": "Requires validation through ticket size, discount rate, credit stress, and real sell-through rather than headline demand." } ], "risk_matrix": [ { "rank": 1, "title_zh": "支付能力不足导致银发自费医疗弹性低于叙事", "title_en": "Silver-economy self-pay purchasing-power shortfall", "chain": "消费与大健康", "chain_en": "consumer and healthcare", "impact": 5, "probability": 4, "severity": 20, "summary_zh": "养老金、地产财富效应和子女转移支付约束可能削弱高端自费医疗，只保留医保、长护险和康复辅具的刚性底座。", "summary_en": "Pension, housing wealth, and intergenerational-transfer constraints can weaken premium self-pay healthcare, leaving reimbursement, long-term care, and rehabilitation devices as the rigid base.", "href": "" }, { "rank": 2, "title_zh": "渠道补库被误读为真实动销", "title_en": "Channel restocking mistaken for real sell-through", "chain": "消费与大健康", "chain_en": "consumer and healthcare", "impact": 4, "probability": 4, "severity": 16, "summary_zh": "食品加工、B端餐饮、代糖和高端体验消费必须用复购、库存周转、客单价和客户留存验证，而不能只看订单或补库。", "summary_en": "Food processing, B-end catering, sweeteners, and premium experience consumption need validation through repeat purchase, inventory turns, ticket size, and customer retention, not order headlines alone.", "href": "" }, { "rank": 3, "title_zh": "政策支付和设备更新节奏慢于盈利兑现", "title_en": "Policy reimbursement and equipment-renewal timing risk", "chain": "医疗健康", "chain_en": "healthcare", "impact": 4, "probability": 3, "severity": 12, "summary_zh": "医保、长护险和设备更新有政策确定性，但招采、定点和回款若慢于预期，订单会滞留在应收账款中。", "summary_en": "Medical insurance, long-term care insurance, and equipment renewal have policy support, but slow tenders, designation, or collections can trap orders in receivables.", "href": "" }, { "rank": 4, "title_zh": "生物安全与海外监管压低医药出海利润率", "title_en": "Healthcare globalization compliance and regulatory discount", "chain": "医药出海", "chain_en": "outbound healthcare", "impact": 4, "probability": 3, "severity": 12, "summary_zh": "CXO脱钩、FDA检查、关税和合规成本可能压低多肽原料药、创新药BD和海外IVD收入的利润保留率。", "summary_en": "CXO decoupling, FDA inspections, tariffs, and compliance costs can reduce profit retention for peptide APIs, innovative-drug BD, and outbound IVD revenue.", "href": "" }, { "rank": 5, "title_zh": "GLP-1和减糖趋势的需求外推过快", "title_en": "GLP-1 and sugar-reduction demand extrapolation risk", "chain": "消费与大健康", "chain_en": "consumer and healthcare", "impact": 3, "probability": 4, "severity": 12, "summary_zh": "减糖趋势具备结构性，但价格下行、产能释放和终端配方替换速度会决定阿洛酮糖利润率。", "summary_en": "Sugar reduction is structural, but price decline, capacity release, and reformulation speed determine allulose margins.", "href": "" }, { "rank": 6, "title_zh": "高端体验消费韧性集中于少数人群", "title_en": "Premium-experience resilience concentrated in a narrow cohort", "chain": "可选消费", "chain_en": "discretionary consumption", "impact": 3, "probability": 4, "severity": 12, "summary_zh": "高端体验消费可能只反映高收入人群韧性，不能直接推导大众消费或自费医疗全面修复。", "summary_en": "Premium experience consumption may reflect high-income resilience rather than broad consumption or self-pay healthcare recovery.", "href": "" } ], "chain_evidence": [ { "chain": "生产率与效率", "chain_en": "productivity and efficiency", "latest": 7, "recent": 21, "risk": 16, "heat": 52.7 }, { "chain": "宏观通胀传导", "chain_en": "macro inflation transmission", "latest": 274, "recent": 1171, "risk": 885, "heat": 2695.2 } ], "tables": { "by_kind": { "transmission_framework": { "zh": { "headers": [ "层级", "主要变量", "财务传导", "投资含义" ], "rows": [ { "层级": "支付层", "主要变量": "养老金、工资收入、地产财富效应、消费信贷", "财务传导": "决定自费医疗、高端体验和耐用品更新的上限", "投资含义": "先看现金流，不先看人口规模" }, { "层级": "政策层", "主要变量": "医保、长护险、设备更新、集采、地方财政", "财务传导": "决定刚性医疗需求能否变成订单和回款", "投资含义": "政策确定性需要折算拨付节奏" }, { "层级": "渠道层", "主要变量": "B端餐饮客户、终端复购、库存周转、折扣率", "财务传导": "验证补库是否为真实动销", "投资含义": "避免把渠道库存当作消费复苏" }, { "层级": "供给层", "主要变量": "产能、成本曲线、合规、质量和交付", "财务传导": "决定收入增长能否保住毛利率", "投资含义": "成本领先和合规交付应获得溢价" }, { "层级": "估值层", "主要变量": "A/H股流动性、海外合规折价、主题拥挤度", "财务传导": "决定确定性与弹性资产的仓位权重", "投资含义": "把底仓和战术仓分开定价" } ], "kind": "transmission_framework" }, "en": { "headers": [ "Layer", "Main variables", "Financial transmission", "Investment implication" ], "rows": [ { "Layer": "Payment", "Main variables": "Pensions, wage income, housing wealth effect, consumer credit", "Financial transmission": "Sets the ceiling for self-pay healthcare, premium experience, and durable replacement", "Investment implication": "Start with cash flow, not population size" }, { "Layer": "Policy", "Main variables": "Medical insurance, long-term care insurance, equipment renewal, procurement, local fiscal budget", "Financial transmission": "Determines whether rigid healthcare demand becomes orders and collections", "Investment implication": "Policy certainty must be adjusted for payment timing" }, { "Layer": "Channel", "Main variables": "B-end catering clients, terminal repeat purchase, inventory turns, discount rate", "Financial transmission": "Tests whether restocking is real sell-through", "Investment implication": "Avoid treating channel inventory as consumption recovery" }, { "Layer": "Supply", "Main variables": "Capacity, cost curve, compliance, quality, delivery", "Financial transmission": "Determines whether revenue growth protects gross margin", "Investment implication": "Cost leadership and compliant delivery deserve premium valuation" }, { "Layer": "Valuation", "Main variables": "A/H liquidity, overseas compliance discount, theme crowding", "Financial transmission": "Sets weights for certainty assets versus high-beta assets", "Investment implication": "Price core holdings and tactical positions separately" } ], "kind": "transmission_framework" } }, "scenario_analysis": { "zh": { "headers": [ "情景", "触发条件", "宏观/资产含义", "投资动作" ], "rows": [ { "情景": "刚性底座兑现", "触发条件": "医保/长护险支出、康复设备招标、慢病用药放量同步改善", "宏观/资产含义": "消费降级中形成防御性成长", "投资动作": "提高医保链、康复和现金流确定资产权重" }, { "情景": "结构成长扩散", "触发条件": "B端餐饮复购、阿洛酮糖价格稳定、GLP-1减糖需求持续", "宏观/资产含义": "食品加工和健康配料利润率改善", "投资动作": "配置成本领先和渠道验证充分的龙头" }, { "情景": "支付能力走弱", "触发条件": "消费信贷恶化、房价财富效应不修复、自费医疗降速", "宏观/资产含义": "高端体验和自费医疗估值下修", "投资动作": "降低纯概念和高端自费赛道权重" }, { "情景": "出海折价扩大", "触发条件": "Biosecure/FDA/关税压力上升，BD回款慢于预期", "宏观/资产含义": "医药出海收入打折、A/H估值分化", "投资动作": "偏向国内刚需与海外现金流已验证标的" } ], "kind": "scenario_analysis" }, "en": { "headers": [ "Scenario", "Trigger", "Macro/asset implication", "Investor action" ], "rows": [ { "Scenario": "Rigid base clears", "Trigger": "Medical/long-term care spending, rehab-device tenders, and chronic-drug uptake improve together", "Macro/asset implication": "Defensive growth forms inside consumer downgrade", "Investor action": "Raise reimbursement-chain, rehab, and cash-flow-certain exposure" }, { "Scenario": "Structural growth spreads", "Trigger": "B-end catering repeat orders, stable allulose pricing, persistent GLP-1 sugar-reduction demand", "Macro/asset implication": "Food-processing and healthy-ingredient margins improve", "Investor action": "Own cost leaders with strong channel validation" }, { "Scenario": "Purchasing power weakens", "Trigger": "Consumer credit worsens, housing wealth effect does not recover, self-pay healthcare slows", "Macro/asset implication": "Premium experience and self-pay healthcare valuations fall", "Investor action": "Cut generic concepts and premium self-pay exposure" }, { "Scenario": "Outbound discount widens", "Trigger": "Biosecure/FDA/tariff pressure rises; BD collections lag expectations", "Macro/asset implication": "Outbound healthcare revenue gets discounted; A/H valuations diverge", "Investor action": "Prefer domestic rigid demand and verified overseas cash flow" } ], "kind": "scenario_analysis" } }, "portfolio_buckets": { "zh": { "headers": [ "组合", "投资暴露", "配置逻辑", "关键检查项" ], "rows": [ { "组合": "核心底仓", "投资暴露": "医保放量确定、慢病/自免药、IVD出海、康复设备、家用辅具", "配置逻辑": "刚性支付和政策确定性更强，抗消费降级能力较好", "关键检查项": "医保执行、院内放量、海外现金流、招投标回款" }, { "组合": "结构成长", "投资暴露": "B端食品加工、冷冻烘焙、预制食材、阿洛酮糖和减糖配料", "配置逻辑": "餐饮降本与健康替代形成双需求曲线", "关键检查项": "客户留存、复购率、库存周转、成本曲线、价格下行速度" }, { "组合": "战术弹性", "投资暴露": "GLP-1多肽原料药、创新药BD、A股医疗设备更新事件", "配置逻辑": "弹性高但受监管、订单落地和资金拨付影响", "关键检查项": "FDA检查、海外大单、BD付款、财政下达、产能审批" }, { "组合": "谨慎或低配", "投资暴露": "高端体检、抗衰、医美、高端体验消费、泛银发概念", "配置逻辑": "高度依赖自费弹性和高收入人群，容易被估值过度外推", "关键检查项": "客单价、折扣率、复购、房价财富效应、消费信贷逾期" }, { "组合": "对冲变量", "投资暴露": "消费信贷恶化、政策拨付延迟、海外合规和汇率", "配置逻辑": "用于校正自费需求、出海利润率和估值久期", "关键检查项": "信用卡/贷款数据、政策文件、FDA/关税事件、离岸美元流" } ], "kind": "portfolio_buckets" }, "en": { "headers": [ "Bucket", "Exposure", "Rationale", "Key checks" ], "rows": [ { "Bucket": "Core holdings", "Exposure": "Reimbursement-backed drugs, chronic and autoimmune medicines, outbound IVD, rehabilitation equipment, home assistive devices", "Rationale": "Rigid payment and policy certainty offer better resistance to consumer downgrade", "Key checks": "Reimbursement execution, hospital uptake, overseas cash flow, tender collections" }, { "Bucket": "Structural growth", "Exposure": "B-end food processing, frozen bakery, prepared ingredients, allulose and sugar-reduction inputs", "Rationale": "Restaurant cost reduction and healthier substitution create two demand curves", "Key checks": "Customer retention, repeat purchase, inventory turns, cost curve, price decline pace" }, { "Bucket": "Tactical beta", "Exposure": "GLP-1 peptide APIs, innovative-drug BD, A-share medical-equipment renewal events", "Rationale": "High upside but exposed to regulation, order conversion, and fiscal payment timing", "Key checks": "FDA inspections, overseas orders, BD payments, fiscal releases, capacity approvals" }, { "Bucket": "Cautious/underweight", "Exposure": "Premium checkups, anti-aging, aesthetic medicine, premium experience consumption, generic silver-economy concepts", "Rationale": "Highly dependent on self-pay elasticity and high-income cohorts; easy to over-extrapolate", "Key checks": "Ticket size, discount rate, repeat purchase, housing wealth effect, consumer-credit delinquencies" }, { "Bucket": "Hedges", "Exposure": "Consumer-credit deterioration, policy payment delay, overseas compliance, FX", "Rationale": "Corrects self-pay demand, outbound margin, and valuation duration", "Key checks": "Credit-card/loan data, policy documents, FDA/tariff events, offshore-dollar flows" } ], "kind": "portfolio_buckets" } }, "monitoring_dashboard": { "zh": { "headers": [ "维度", "指标", "如何解读", "证据来源" ], "rows": [ { "维度": "支付能力", "指标": "养老金缴存/领取、医保和长护险支出、消费信贷逾期", "如何解读": "支付能力改善支持自费弹性；恶化则偏向刚性医保链", "证据来源": "人社/医保数据、金融机构披露、地方预算" }, { "维度": "动销质量", "指标": "B端客户复购、库存周转、终端折扣、客单价", "如何解读": "复购和周转改善才说明需求真实，不只是补库", "证据来源": "渠道调研、公司月度经营、餐饮客户订单" }, { "维度": "医疗兑现", "指标": "医保准入、进院速度、设备更新招标、回款周期", "如何解读": "政策确定性需要转成医院使用和现金回款", "证据来源": "医保目录、招投标平台、公司公告" }, { "维度": "出海风险", "指标": "FDA检查、Biosecure Act、关税、BD付款与美元留存", "如何解读": "决定海外收入的利润保留率和估值折价", "证据来源": "监管公告、海关/订单、公司合同披露" }, { "维度": "估值拥挤", "指标": "A/H股换手率、资金流、估值分位、主题交易集中度", "如何解读": "拥挤时要提高兑现要求，避免单纯主题溢价", "证据来源": "交易所数据、ETF/北向/南向资金、行业估值" } ], "kind": "monitoring_dashboard" }, "en": { "headers": [ "Dimension", "Indicator", "Interpretation", "Evidence source" ], "rows": [ { "Dimension": "Purchasing power", "Indicator": "Pension contributions/payouts, medical and long-term care insurance spending, consumer-credit delinquencies", "Interpretation": "Improvement supports self-pay elasticity; deterioration favors rigid reimbursement chains", "Evidence source": "Human resources, medical-insurance data, financial disclosures, local budgets" }, { "Dimension": "Sell-through quality", "Indicator": "B-end repeat purchase, inventory turns, terminal discounting, ticket size", "Interpretation": "Better repeat purchase and turns prove demand; restocking alone does not", "Evidence source": "Channel checks, company monthly operations, restaurant client orders" }, { "Dimension": "Healthcare conversion", "Indicator": "Reimbursement access, hospital uptake, equipment-renewal tenders, collection cycle", "Interpretation": "Policy certainty must become hospital usage and cash collection", "Evidence source": "Medical-insurance catalogues, tender platforms, company announcements" }, { "Dimension": "Outbound risk", "Indicator": "FDA inspections, Biosecure Act, tariffs, BD payments, offshore-dollar retention", "Interpretation": "Determines profit retention and valuation discount for overseas revenue", "Evidence source": "Regulatory notices, customs/orders, contract disclosures" }, { "Dimension": "Valuation crowding", "Indicator": "A/H turnover, flows, valuation percentile, theme concentration", "Interpretation": "Crowded trades require stronger execution evidence", "Evidence source": "Exchange data, ETF and Stock Connect flows, sector valuation" } ], "kind": "monitoring_dashboard" } } }, "all": { "zh": [ { "headers": [ "层级", "主要变量", "财务传导", "投资含义" ], "rows": [ { "层级": "支付层", "主要变量": "养老金、工资收入、地产财富效应、消费信贷", "财务传导": "决定自费医疗、高端体验和耐用品更新的上限", "投资含义": "先看现金流，不先看人口规模" }, { "层级": "政策层", "主要变量": "医保、长护险、设备更新、集采、地方财政", "财务传导": "决定刚性医疗需求能否变成订单和回款", "投资含义": "政策确定性需要折算拨付节奏" }, { "层级": "渠道层", "主要变量": "B端餐饮客户、终端复购、库存周转、折扣率", "财务传导": "验证补库是否为真实动销", "投资含义": "避免把渠道库存当作消费复苏" }, { "层级": "供给层", "主要变量": "产能、成本曲线、合规、质量和交付", "财务传导": "决定收入增长能否保住毛利率", "投资含义": "成本领先和合规交付应获得溢价" }, { "层级": "估值层", "主要变量": "A/H股流动性、海外合规折价、主题拥挤度", "财务传导": "决定确定性与弹性资产的仓位权重", "投资含义": "把底仓和战术仓分开定价" } ], "kind": "transmission_framework" }, { "headers": [ "情景", "触发条件", "宏观/资产含义", "投资动作" ], "rows": [ { "情景": "刚性底座兑现", "触发条件": "医保/长护险支出、康复设备招标、慢病用药放量同步改善", "宏观/资产含义": "消费降级中形成防御性成长", "投资动作": "提高医保链、康复和现金流确定资产权重" }, { "情景": "结构成长扩散", "触发条件": "B端餐饮复购、阿洛酮糖价格稳定、GLP-1减糖需求持续", "宏观/资产含义": "食品加工和健康配料利润率改善", "投资动作": "配置成本领先和渠道验证充分的龙头" }, { "情景": "支付能力走弱", "触发条件": "消费信贷恶化、房价财富效应不修复、自费医疗降速", "宏观/资产含义": "高端体验和自费医疗估值下修", "投资动作": "降低纯概念和高端自费赛道权重" }, { "情景": "出海折价扩大", "触发条件": "Biosecure/FDA/关税压力上升，BD回款慢于预期", "宏观/资产含义": "医药出海收入打折、A/H估值分化", "投资动作": "偏向国内刚需与海外现金流已验证标的" } ], "kind": "scenario_analysis" }, { "headers": [ "组合", "投资暴露", "配置逻辑", "关键检查项" ], "rows": [ { "组合": "核心底仓", "投资暴露": "医保放量确定、慢病/自免药、IVD出海、康复设备、家用辅具", "配置逻辑": "刚性支付和政策确定性更强，抗消费降级能力较好", "关键检查项": "医保执行、院内放量、海外现金流、招投标回款" }, { "组合": "结构成长", "投资暴露": "B端食品加工、冷冻烘焙、预制食材、阿洛酮糖和减糖配料", "配置逻辑": "餐饮降本与健康替代形成双需求曲线", "关键检查项": "客户留存、复购率、库存周转、成本曲线、价格下行速度" }, { "组合": "战术弹性", "投资暴露": "GLP-1多肽原料药、创新药BD、A股医疗设备更新事件", "配置逻辑": "弹性高但受监管、订单落地和资金拨付影响", "关键检查项": "FDA检查、海外大单、BD付款、财政下达、产能审批" }, { "组合": "谨慎或低配", "投资暴露": "高端体检、抗衰、医美、高端体验消费、泛银发概念", "配置逻辑": "高度依赖自费弹性和高收入人群，容易被估值过度外推", "关键检查项": "客单价、折扣率、复购、房价财富效应、消费信贷逾期" }, { "组合": "对冲变量", "投资暴露": "消费信贷恶化、政策拨付延迟、海外合规和汇率", "配置逻辑": "用于校正自费需求、出海利润率和估值久期", "关键检查项": "信用卡/贷款数据、政策文件、FDA/关税事件、离岸美元流" } ], "kind": "portfolio_buckets" }, { "headers": [ "维度", "指标", "如何解读", "证据来源" ], "rows": [ { "维度": "支付能力", "指标": "养老金缴存/领取、医保和长护险支出、消费信贷逾期", "如何解读": "支付能力改善支持自费弹性；恶化则偏向刚性医保链", "证据来源": "人社/医保数据、金融机构披露、地方预算" }, { "维度": "动销质量", "指标": "B端客户复购、库存周转、终端折扣、客单价", "如何解读": "复购和周转改善才说明需求真实，不只是补库", "证据来源": "渠道调研、公司月度经营、餐饮客户订单" }, { "维度": "医疗兑现", "指标": "医保准入、进院速度、设备更新招标、回款周期", "如何解读": "政策确定性需要转成医院使用和现金回款", "证据来源": "医保目录、招投标平台、公司公告" }, { "维度": "出海风险", "指标": "FDA检查、Biosecure Act、关税、BD付款与美元留存", "如何解读": "决定海外收入的利润保留率和估值折价", "证据来源": "监管公告、海关/订单、公司合同披露" }, { "维度": "估值拥挤", "指标": "A/H股换手率、资金流、估值分位、主题交易集中度", "如何解读": "拥挤时要提高兑现要求，避免单纯主题溢价", "证据来源": "交易所数据、ETF/北向/南向资金、行业估值" } ], "kind": "monitoring_dashboard" } ], "en": [ { "headers": [ "Layer", "Main variables", "Financial transmission", "Investment implication" ], "rows": [ { "Layer": "Payment", "Main variables": "Pensions, wage income, housing wealth effect, consumer credit", "Financial transmission": "Sets the ceiling for self-pay healthcare, premium experience, and durable replacement", "Investment implication": "Start with cash flow, not population size" }, { "Layer": "Policy", "Main variables": "Medical insurance, long-term care insurance, equipment renewal, procurement, local fiscal budget", "Financial transmission": "Determines whether rigid healthcare demand becomes orders and collections", "Investment implication": "Policy certainty must be adjusted for payment timing" }, { "Layer": "Channel", "Main variables": "B-end catering clients, terminal repeat purchase, inventory turns, discount rate", "Financial transmission": "Tests whether restocking is real sell-through", "Investment implication": "Avoid treating channel inventory as consumption recovery" }, { "Layer": "Supply", "Main variables": "Capacity, cost curve, compliance, quality, delivery", "Financial transmission": "Determines whether revenue growth protects gross margin", "Investment implication": "Cost leadership and compliant delivery deserve premium valuation" }, { "Layer": "Valuation", "Main variables": "A/H liquidity, overseas compliance discount, theme crowding", "Financial transmission": "Sets weights for certainty assets versus high-beta assets", "Investment implication": "Price core holdings and tactical positions separately" } ], "kind": "transmission_framework" }, { "headers": [ "Scenario", "Trigger", "Macro/asset implication", "Investor action" ], "rows": [ { "Scenario": "Rigid base clears", "Trigger": "Medical/long-term care spending, rehab-device tenders, and chronic-drug uptake improve together", "Macro/asset implication": "Defensive growth forms inside consumer downgrade", "Investor action": "Raise reimbursement-chain, rehab, and cash-flow-certain exposure" }, { "Scenario": "Structural growth spreads", "Trigger": "B-end catering repeat orders, stable allulose pricing, persistent GLP-1 sugar-reduction demand", "Macro/asset implication": "Food-processing and healthy-ingredient margins improve", "Investor action": "Own cost leaders with strong channel validation" }, { "Scenario": "Purchasing power weakens", "Trigger": "Consumer credit worsens, housing wealth effect does not recover, self-pay healthcare slows", "Macro/asset implication": "Premium experience and self-pay healthcare valuations fall", "Investor action": "Cut generic concepts and premium self-pay exposure" }, { "Scenario": "Outbound discount widens", "Trigger": "Biosecure/FDA/tariff pressure rises; BD collections lag expectations", "Macro/asset implication": "Outbound healthcare revenue gets discounted; A/H valuations diverge", "Investor action": "Prefer domestic rigid demand and verified overseas cash flow" } ], "kind": "scenario_analysis" }, { "headers": [ "Bucket", "Exposure", "Rationale", "Key checks" ], "rows": [ { "Bucket": "Core holdings", "Exposure": "Reimbursement-backed drugs, chronic and autoimmune medicines, outbound IVD, rehabilitation equipment, home assistive devices", "Rationale": "Rigid payment and policy certainty offer better resistance to consumer downgrade", "Key checks": "Reimbursement execution, hospital uptake, overseas cash flow, tender collections" }, { "Bucket": "Structural growth", "Exposure": "B-end food processing, frozen bakery, prepared ingredients, allulose and sugar-reduction inputs", "Rationale": "Restaurant cost reduction and healthier substitution create two demand curves", "Key checks": "Customer retention, repeat purchase, inventory turns, cost curve, price decline pace" }, { "Bucket": "Tactical beta", "Exposure": "GLP-1 peptide APIs, innovative-drug BD, A-share medical-equipment renewal events", "Rationale": "High upside but exposed to regulation, order conversion, and fiscal payment timing", "Key checks": "FDA inspections, overseas orders, BD payments, fiscal releases, capacity approvals" }, { "Bucket": "Cautious/underweight", "Exposure": "Premium checkups, anti-aging, aesthetic medicine, premium experience consumption, generic silver-economy concepts", "Rationale": "Highly dependent on self-pay elasticity and high-income cohorts; easy to over-extrapolate", "Key checks": "Ticket size, discount rate, repeat purchase, housing wealth effect, consumer-credit delinquencies" }, { "Bucket": "Hedges", "Exposure": "Consumer-credit deterioration, policy payment delay, overseas compliance, FX", "Rationale": "Corrects self-pay demand, outbound margin, and valuation duration", "Key checks": "Credit-card/loan data, policy documents, FDA/tariff events, offshore-dollar flows" } ], "kind": "portfolio_buckets" }, { "headers": [ "Dimension", "Indicator", "Interpretation", "Evidence source" ], "rows": [ { "Dimension": "Purchasing power", "Indicator": "Pension contributions/payouts, medical and long-term care insurance spending, consumer-credit delinquencies", "Interpretation": "Improvement supports self-pay elasticity; deterioration favors rigid reimbursement chains", "Evidence source": "Human resources, medical-insurance data, financial disclosures, local budgets" }, { "Dimension": "Sell-through quality", "Indicator": "B-end repeat purchase, inventory turns, terminal discounting, ticket size", "Interpretation": "Better repeat purchase and turns prove demand; restocking alone does not", "Evidence source": "Channel checks, company monthly operations, restaurant client orders" }, { "Dimension": "Healthcare conversion", "Indicator": "Reimbursement access, hospital uptake, equipment-renewal tenders, collection cycle", "Interpretation": "Policy certainty must become hospital usage and cash collection", "Evidence source": "Medical-insurance catalogues, tender platforms, company announcements" }, { "Dimension": "Outbound risk", "Indicator": "FDA inspections, Biosecure Act, tariffs, BD payments, offshore-dollar retention", "Interpretation": "Determines profit retention and valuation discount for overseas revenue", "Evidence source": "Regulatory notices, customs/orders, contract disclosures" }, { "Dimension": "Valuation crowding", "Indicator": "A/H turnover, flows, valuation percentile, theme concentration", "Interpretation": "Crowded trades require stronger execution evidence", "Evidence source": "Exchange data, ETF and Stock Connect flows, sector valuation" } ], "kind": "monitoring_dashboard" } ] } }, "assets": [ { "id": "chain-evidence", "label_zh": "产业链证据密度", "label_en": "Industry-chain evidence density", "path": "outputs/deep-research/reports/consumer-downgrade-health-silver-economy-78a2530a/assets/chain-evidence.png", "href": "/deep-research/consumer-downgrade-health-silver-economy-78a2530a/assets/chain-evidence.png" }, { "id": "transmission-map", "label_zh": "传导机制图", "label_en": "Transmission map", "path": "outputs/deep-research/reports/consumer-downgrade-health-silver-economy-78a2530a/assets/transmission-map.png", "href": "/deep-research/consumer-downgrade-health-silver-economy-78a2530a/assets/transmission-map.png" }, { "id": "risk-matrix", "label_zh": "风险矩阵", "label_en": "Risk matrix", "path": "outputs/deep-research/reports/consumer-downgrade-health-silver-economy-78a2530a/assets/risk-matrix.png", "href": "/deep-research/consumer-downgrade-health-silver-economy-78a2530a/assets/risk-matrix.png" } ], "documents": { "markdown_en": "outputs/deep-research/reports/consumer-downgrade-health-silver-economy-78a2530a/report_en.md", "markdown_zh": "outputs/deep-research/reports/consumer-downgrade-health-silver-economy-78a2530a/report_zh.md", "docx_en": "outputs/deep-research/reports/consumer-downgrade-health-silver-economy-78a2530a/report_en.docx", "docx_zh": "outputs/deep-research/reports/consumer-downgrade-health-silver-economy-78a2530a/report_zh.docx", "pdf_en": "outputs/deep-research/reports/consumer-downgrade-health-silver-economy-78a2530a/report_en.pdf", "pdf_zh": "outputs/deep-research/reports/consumer-downgrade-health-silver-economy-78a2530a/report_zh.pdf", "json": "outputs/deep-research/reports/consumer-downgrade-health-silver-economy-78a2530a/report.json" }, "web": { "site_href": "deep-research/consumer-downgrade-health-silver-economy-78a2530a/index.html", "frontend_href": "/deep-research/consumer-downgrade-health-silver-economy-78a2530a", "downloads": [ { "label": "Markdown EN", "file": "report_en.md", "path": "outputs/deep-research/reports/consumer-downgrade-health-silver-economy-78a2530a/report_en.md", "href": "/deep-research/downloads/consumer-downgrade-health-silver-economy-78a2530a/report_en.md" }, { "label": "Markdown ZH", "file": "report_zh.md", "path": "outputs/deep-research/reports/consumer-downgrade-health-silver-economy-78a2530a/report_zh.md", "href": "/deep-research/downloads/consumer-downgrade-health-silver-economy-78a2530a/report_zh.md" }, { "label": "DOCX EN", "file": "report_en.docx", "path": "outputs/deep-research/reports/consumer-downgrade-health-silver-economy-78a2530a/report_en.docx", "href": "/deep-research/downloads/consumer-downgrade-health-silver-economy-78a2530a/report_en.docx" }, { "label": "DOCX ZH", "file": "report_zh.docx", "path": "outputs/deep-research/reports/consumer-downgrade-health-silver-economy-78a2530a/report_zh.docx", "href": "/deep-research/downloads/consumer-downgrade-health-silver-economy-78a2530a/report_zh.docx" }, { "label": "PDF EN", "file": "report_en.pdf", "path": "outputs/deep-research/reports/consumer-downgrade-health-silver-economy-78a2530a/report_en.pdf", "href": "/deep-research/downloads/consumer-downgrade-health-silver-economy-78a2530a/report_en.pdf" }, { "label": "PDF ZH", "file": "report_zh.pdf", "path": "outputs/deep-research/reports/consumer-downgrade-health-silver-economy-78a2530a/report_zh.pdf", "href": "/deep-research/downloads/consumer-downgrade-health-silver-economy-78a2530a/report_zh.pdf" }, { "label": "Structured JSON", "file": "report.json", "path": "outputs/deep-research/reports/consumer-downgrade-health-silver-economy-78a2530a/report.json", "href": "/deep-research/downloads/consumer-downgrade-health-silver-economy-78a2530a/report.json" } ] } }